You are here

  • Home
  • Archive
  • Volume 93, Issue Suppl 1
  • J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Citation Tools

Article menu
Download PDFPDF
J: Clinical therapeutics
J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Furr Stimming E, Sung V, Testa C, et al
J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)
Journal of Neurology, Neurosurgery & Psychiatry 2022;93:A95.